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ABSTRACT Mycobacterium tuberculosis, the etiological agent of tuberculosis (TB), has a unique cell envelope which accounts
for its unusual low permeability and contributes to resistance against common antibiotics. The main structural elements of the
cell wall consist of a cross-linked network of peptidoglycan (PG) in which some of the muramic acid residues are covalently at-
tached to a complex polysaccharide, arabinogalactan (AG), via a unique -L-rhamnopyranose–(1¡3)--D-GlcNAc-(1¡P) linker
unit. While the molecular genetics associated with PG and AG biosynthetic pathways have been largely delineated, the mecha-
nism by which these two major pathways converge has remained elusive. In Gram-positive organisms, the LytR-CpsA-Psr (LCP)
family of proteins are responsible for ligating cell wall teichoic acids to peptidoglycan, through a linker unit that bears a striking
resemblance to that found in mycobacterial arabinogalactan. In this study, we have identified Rv3267 as a mycobacterial LCP
homolog gene that encodes a phosphotransferase which we have named Lcp1. We demonstrate that lcp1 is an essential gene re-
quired for cell viability and show that recombinant Lcp1 is capable of ligating AG to PG in a cell-free radiolabeling assay.
IMPORTANCE Tuberculosis is an infectious disease caused by the bacterial organism Mycobacterium tuberculosis. Survival of
M. tuberculosis rests critically on the integrity of its unique cell wall; therefore, a better understanding of how the genes and en-
zymes involved in cell wall assembly work is fundamental for us to develop new drugs to treat this disease. In this study, we have
identified Lcp1 as an essential phosphotransferase that ligates together arabinogalactan and peptidoglycan, two crucial cell wall
macromolecules found within the mycobacterial cell wall. The discovery of Lcp1 sheds new light on the final stages of mycobac-
terial cell wall assembly and represents a key biosynthetic step that could be exploited for new anti-TB drug discovery.
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Tuberculosis (TB) remains the single most important bacterialcause of global mortality and morbidity, causing around 9.6
million new cases and 1.5 million deaths each year (1). This prev-
alence is largely due to the increased susceptibility of HIV-infected
individuals, and the rise of multidrug-resistant (MDR), exten-
sively drug-resistant (XDR), and, more recently, totally drug-
resistant (TDR) TB strains (2). It is of paramount importance that
we extend our understanding of the pathogenicity and physiology
of the tubercle bacillus in the hope of priming novel therapeutic
approaches against this ancient human adversary. Mycobacterial
peptidoglycan (PG) forms the basal layer of the mycolyl-arabi-
nogalactan–peptidoglycan (mAGP) complex and is composed of
alternating N-acetylglucosamine (GlcNAc) and modified mu-
ramic acid (Mur) residues, linked in a (1¡4) configuration (3).
Unlike archetypal PG commonly found in bacteria such as Esche-
richia coli, the muramic acid residues in Mycobacterium tubercu-
losis contains a mixture of N-acetyl and N-glycolyl derivatives,
whereby the N-acetyl function has been oxidized to an N-glycolyl
function to form MurNGly (4–6). In addition, approximately 10
to 12% of the muramic acid residues of PG are covalently tethered
to arabinogalactan (AG) via a phosphodiester bond (7). The
6=-OH groups of these muramic acid residues serve as attachment
sites forming a phosphodiester bond via a unique -L-
rhamnopyranose–(1¡3)--D-GlcNAc-(1¡P) linker unit (LU)
(8). Collectively, PG and AG form a huge macropolymer posi-
tioned between the cytoplasmic membrane and the outer mycolic
acid layer of the TB bacillus. Our understanding of both the struc-
ture and biosynthesis of mycobacterial AG has developed steadily
over the last 2 decades, with much emphasis being placed on in-
vestigating the molecular genetics of how this complex structure is
assembled (extensively reviewed in reference 9). While the cyto-
plasmic and extracytoplasmic intermediate biosynthetic steps of
cell wall assembly have been almost fully delineated, our under-
standing of the latter stages of AG biosynthesis, specifically the
attachment of AG to PG, remains fragmented at best. Previous
studies have demonstrated that attachment of AG to the mycobac-
terial cell wall occurs only when the PG has been fully matured via
the cross-linking action of endogenous transpeptidases (10).
However, the enzyme responsible for this action remains elusive.
In Gram-positive bacteria, the structure of the linker unit (D-
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GlcNAc-D-ManNAc) that connects wall teichoic acids (WTA) to
PG via a phosphodiester bond is remarkably similar to the linker
unit found within theM. tuberculosis cell wall (D-GlcNAc-L-Rhap)
(11). Other commonalities also exist between mycobacterial and
Gram-positive cell wall glycan biosynthetic pathways. For in-
stance, in organisms such as Staphylococcus aureus polyribitol-
phosphate (Rbo-P) is assembled upon a polyprenyl pyrophospho-
ryl lipid carrier which, after biosynthesis is completed, is
ultimately attached to the C6-hydroxyl of MurNAc within the PG
glycan strands (8, 11). Mycobacterial AG is also assembled upon a
polyprenyl pyrophosphoryl lipid carrier before its final deposition
onto specific muramic acid residues of PG (12). We postulated
that WTA-containing Gram-positive organisms and members of
the Actinomycetales might utilize similar ligases from the same
protein superfamily. Kawai et al. conducted a structural and ge-
netic study and proposed that a family of genes encoding the LytR-
CpsA-Psr (LCP) proteins catalyze the ligation of the murine link-
age unit of WTA to the MurNAc units of PG in Bacillus subtilis
(13). More recent studies have revealed further corroborating ev-
idence that the LCP family of proteins are responsible for attach-
ing capsular polysaccharides to the murine sacculus of S. aureus
(14) and Streptococcus pneumoniae (15). Here, we demonstrate
that the open reading frame contained in Rv3267, one of three
LCP ortholog genes in M. tuberculosis, encodes a peptidoglycan–
arabinogalactan ligase, which we have termed Lcp1.
RESULTS
Genome comparison of the Lcp1 locus. Using S. aureus, S. pneu-
moniae, and B. subtilis LCP proteins as search sequences, we per-
formed a bioinformatic analysis of mycobacterial and corynebac-
terial genomes to identify putative genes that might encode the
mycobacterial LCP homologs (see Fig. S1 in the supplemental
material). We identified three putative LCP homologs in M. tu-
berculosis, with Rv3267 sharing 20% amino acid sequence identity
with Cps2A from S. pneumoniae, which is in accordance with a
previous phylogenetic study of bacterial LCP proteins (16). The
remaining two putative LCP orthologs present in M. tuberculosis,
encoded by Rv3484 and Rv0822c, share 15% and 12% amino acid
identity with Cps2A from S. pneumoniae. Rv3267 shares 36% and
26% amino acid sequence identity with Rv3484 and Rv0822c, re-
spectively. Both Rv3484 and Rv0822c are predicted to contain a
single N-terminal transmembrane (TM)-helix, similar to that of
Rv3267, and are predicted to contain domains belonging to both
LCP and LytR_C superfamilies. Interestingly, the genome of My-
cobacterium leprae, which shows massive gene decay and is thus
considered to represent a “minimal” mycobacterial genome, has
retained only two LCP orthologs in the form of ML0750 and
ML2247, sharing 79.1% and 32.7% amino acid sequence identity
with Rv3267, respectively. Inspection of the Mycobacterium smeg-
matis genome reveals four putative orthologs, MSMEG_1824,
MSMEG_6421, MSMEG_0107, and MSMEG_5775, each sharing
amino acid sequence identities of 72%, 35%, 31%, and 24% with
Rv3267, respectively. Furthermore, an alignment of the genes sur-
rounding Rv3267 reveals genetic synteny with orthologous re-
gions from M. smegmatis, M. leprae, and Corynebacterium glu-
tamicum (Fig. 1A). This close arrangement of genes is highly
indicative of conserved functionality. Interestingly, Rv3267 is po-
sitioned immediately upstream of rmlD andwbbL1, both of which
FIG 1 Comparison of the lcp1 locus and in silico analysis of Lcp1 by TMHMM and I-TASSER. (A) The locus in bacteria analyzed consists of lcp1, which in
M. tuberculosis has the locus tag Rv3267 and in M. smegmatis has the locus tag MSMEG1824. For M. leprae and C. glutamicum, locus tags are ML0756 and
NCgl0708, respectively. (B) The TMHMM server was used to predict the membrane topology of MtbLcp1 (48). (C) I-TASSER homology model of MtbLcp1
positioned in relation to the cytoplasmic membrane and predicted N-terminal TM -helix (19).
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encode enzymes responsible for the formation of the linker unit
during early-stage AG biosynthesis (Fig. 1A) (17, 18). Based on
these analyses, we hypothesized that Rv3267 was the primary LCP
homolog responsible for ligating PG to AG in mycobacteria,
which we have named Lcp1.
In silico analysis of MtbLcp1 and identification of copurifying
polyisoprenoid phosphate. Analysis of the M. tuberculosis Lcp1
(MtbLcp1) amino acid sequence suggests that a single
transmembrane-spanning -helix occurs at the N terminus of the
protein (Fig. 1B). Similarly, a single N-terminal transmembrane
-helix has also been observed in other LCP proteins, such as
Cps2A from S. pneumoniae (13, 16). An alignment of the amino
acid sequences of MtbLcp1 and Cps2A from S. pneumoniae indi-
cates that these two proteins share 20% sequence identity (see
Fig. S1 in the supplemental material). The crystal structure of
TM-Cps2A (residues 98 to 481) has been solved to a resolution
of 1.69 Å with one molecule of decaprenol-1-monophosphate
bound in a central hydrophobic cavity (2XXP) (13). Although we
were able to express large amounts of pure, soluble His6-tagged
MtbLcp1 (see below), our attempts to obtain an experimental crys-
tal structure of MtbLcp1 have so far proven unsuccessful. There-
fore, we generated an MtbLcp1 homology model using the
I-TASSER server (utilizing the S. pneumoniae Cps2A structure as
the template), resulting in a C-score of2.64 (19, 20). Unlike the
S. pneumoniae TM-Cps2A structure, which also harbors an
N-terminal accessory domain, the MtbLcp1 amino acid sequence
and homology model suggests that only a single “LCP-like” do-
main is present (Fig. 1C) (13). Our MtbLcp1 homology model
indicates that a 5-stranded -sheet forms the core of the protein,
with -helices surrounding a central -sheet. Our homology
model also retains the polyisoprenoid-binding cavity of Cps2A
(Fig. 1C) (13). Overexpression of His6-tagged MtbLcp1 in E. coli
BL21(DE3) cells and subsequent purification by immobilized
metal affinity chromatography (IMAC) resulted in a preparation
of His6-tagged MtbLcp1 that was stable in solution at a concentra-
tion of 50 mg/ml. Since Cps2A was shown to copurify with a
polyisoprenoid phosphate, we also investigated whether His6-
tagged MtbLcp1 copurified with a similar lipid (13). We performed
an organic solvent extraction on His6-tagged MtbLcp1 followed by
thin-layer chromatography (TLC) analysis, which revealed a spot
that migrated with an Rf identical to that of decaprenyl-1-
monophosphate (Fig. 2A). Mass spectrometric analysis of this co-
purifying lipid revealed an m/z of 777, which correlates with the
expected mass of decaprenyl-1-monophosphate (Fig. 2D). This
evidence was further corroborated by comparison to known stan-
dards of decaprenyl-1-monophsophate and undecaprenyl-1-
monophsophate, which reveal m/z values of 777 and 845, respec-
tively (Fig. 2B and C). We also performed an identical solvent
extraction on a highly purified preparation of EmbCCT (the
C-terminal globular domain of the arabinofuranosyltransferase
EmbC from M. tuberculosis [21]) (Fig. 2A). This negative control
confirms that the product extracted from MtbLcp1 is not a con-
taminating impurity from the extraction process.
MsLcp1 is essential for viability of M. smegmatis. Because of
its putative role in covalently attaching AG to PG in mycobacteria,
we hypothesized that Mtblcp1 would likely be an essential gene. In
order to test this hypothesis, we used M. smegmatis as a model
system to investigate the essentiality of Lcp1 in mycobacteria using
the conditional expression specialized transduction essentiality
test (CESTET) (22–25). We constructed a knockout phage,
phMslcp1, designed to replace MSMEG1824 (M. smegmatis lcp1
[Mslcp1]) with a hygromycin resistance cassette (22), but as pre-
dicted, we were unable to directly generate a null mutant due to
the failure to yield any transductants. However, we were able to
generate an Mslcp1 null mutant (M. smegmatis Mslcp1 pMV306-
ACET-Mslcp1) by transducing a merodiploid strain containing a
second, inducible copy of Mslcp1. Expression of this recombinant
copy of Mslcp1 was induced by the addition of acetamide to the
growth medium, and only when this inducer was present on agar
plates were we able to generate conditional knockout mutants. In
this regard, the conditional knockout mutant (M. smegmatis
Mslcp1 pMV306-ACET-Mslcp1) exhibited an altered colony phe-
notype compared to the wild type, which is suggestive of a defect
or lesion in the cell wall, which might not be fully recovered by
complementation via the acetamide-inducible pMV306-ACET-
Mslcp1 plasmid (Fig. 3A). To further investigate the essentiality
of Mslcp1, we cultured M. smegmatis Mslcp1 pMV306-ACET-
Mslcp1 in liquid medium and withdrew the inducer acetamide
from the growth medium, with subsequent measurement of CFU.
We observed a rapid loss of cell viability immediately after acet-
amide was removed from growth medium, indicating that expres-
sion of the pMV306-ACET-driven copy of Mslcp1 was required for
cell growth (Fig. 3B). This confirms that Mslcp1 is indeed essential
in M. smegmatis. The rapid loss in cell viability of the Mslcp1
mutant made any attempt to characterize the resultant phenotype
(specifically cell wall lesions) technically challenging. Therefore,
we turned our attention toward the biochemical characterization
of recombinant MtbLcp1.
Carbohydrate binding of linker unit mimetics to MtbLcp1.
Our laboratory has previously synthesized neoglycolipid accep-
tors modeled on motifs found within mycobacterial AG, which
have been successfully employed to probe both enzymatic func-
tion and ligand binding relationships of cell wall processing en-
zymes (21, 26, 27). In this regard, we synthesized a panel of ana-
logues of the mycobacterial linker unit (compounds 1 to 4)
(Fig. 4A; see also Text S1 in the supplemental material) in order
to probe the interaction of MtbLcp1 with decaprenyl-
pyrophosphoryl-GlcNAc-Rha-Galactose, its natural physio-
logical substrate. Each of the ligands used (compounds 1 to 4)
was synthesized to include an octyl (C8) group attached to the
anomeric carbon. Historically, these alkyl groups are useful for
performing solvent extractions from glycosyltransferase assay
mixtures when used as neoglycolipid acceptors (26). In this
study, their sole use was to mimic the hydrophobicity of the
lipid moiety of the natural substrate, which would be accom-
modated by decaprenyl-pyrophosphate. Due to the chemical
complexity and labile nature of the natural substrate (12, 28),
using synthetic analogues offered us an alternative approach to
investigate the biochemistry of this key enzymatic step. By way
of intrinsic tryptophan fluorescence (ITF), we probed the
binding of four potential ligands (compounds 1 to 4) to Mt-
bLcp1, each of which is a variant of the mycobacterial linker
unit (Fig. 4A). ITF is an extremely useful approach to study
protein-ligand interactions (29) and has been successfully used
by our laboratory to biochemically characterize several myco-
bacterial proteins (21, 27, 30, 31). Fitting the binding data to a
single-site saturation model yielded an equilibrium dissocia-
tion constant, KD, of 57.68 M for compound 1, the ligand
which resembles the mycobacterial linker unit disaccharide
L-Rha-(1¡3)-D-GlcNAc (Fig. 4B). ITF experiments repeated
Lcp1 Ligates AG to PG in M. tuberculosis
















with a tetrasaccharide ligand that resembles an extension of the
linker unit by two Galf residues afforded an ~10-fold increase
in affinity, with a KD of 5.13 M. Further elongation with a
third Galf unit resulted in a calculated KD of 20.39 M. The
cytoplasmic steps of mycobacterial galactan formation proceed
via a linear biosynthetic pathway; therefore, compounds 2 and
3 represent chemical mimetics of glycolipid-3 (GL-3) and
glycolipid-4 (GL-4) intermediates of this pathway, respectively
(12, 28), without the pyrophosphoryl-decaprenyl moiety
linked to the anomeric position of the GlcNAc unit. In addi-
tion, we investigated the binding of a fourth ligand against
MtbLcp1. Compound 4, a disaccharide of D-Galf-(1¡4)-L-
Rhap (27), mimics the terminal component of the linker unit
with a single Galf residue and displays an apparent KD of
97.61 M. However, compound 4 achieves a Bmax of only 177,
which is significantly lower than those of compounds 1 to 3 and
reflects the changes in fluorescence observed upon addition of
equivalent volumes of water. Therefore, compound 4 displays
no significant binding affinity (above background) toward Mt-
bLcp1 in ITF assays (Fig. 4B).
MtbLcp1 ligates newly synthesized galactan to peptidoglycan
in a cell-free assay. We sought to investigate whether MtbLcp1 is
capable of ligating AG to PG (from decaprenyl-pyrophosphoryl-
GlcNAc-Rha-galactose) by developing a cell-free biochemical
functional assay. Since MtbLcp1 contains a single N-terminal TM
-helix, and attachment of AG to PG is likely to occur at or around
the cytoplasmic membrane, we postulated that membranes pre-
pared from mycobacteria should contain endogenous PG-AG li-
gase activity and, as such, could be investigated using an appro-
priate [14C]carbohydrate radiolabeling assay. We have previously
developed a radiolabel assay for monitoring the synthesis of
decaprenyl-pyrophosphoryl-linked intermediates of mycobacte-
rial cell wall biosynthesis (28). In this study, we modified this assay
system so that we could directly investigate the in vitro covalent
attachment of AG intermediates to PG. Briefly, membranes and
the P60 fraction from M. smegmatis (both rich in endogenous cell
wall biosynthetic activity) were combined with substrates in the
form of purified peptidoglycan (PPG) and UDP-[14C]Galp. The
endogenous mutase activity within the P60 fraction of this assay
mix (used to convert UDP-[14C]Galp to UDP-[14C]Galf) was suf-
ficient to allow direct incorporation of [14C]Galf into cell wall
intermediates, as previously demonstrated (12, 28). PPG is a
highly purified preparation of nascent M. smegmatis PG free from
AG covalently attached to the 6=-OH position of MurNAc via a
phosphodiester bond (32). The purpose of PPG is both to provide
a substrate for attachment of 14C-labeled linker unit-galactan in-
termediates and to serve as a “vehicle” for extraction from the
assay mixture for subsequent radiochemical quantification. Fi-
FIG 2 TLC and ES-MS analysis and identification of decaprenyl-1-
monophosphate bound to recombinant MtbLcp1. (A) TLC analysis of organic
extractable material of recombinant MtbLcp1. Standards of decaprenyl-1-
(Continued)
Figure Legend Continued
monophosphate and undecaprenyl-1-monophosphate are in lanes 1 and 2,
respectively. Lane 3 contains material extracted from MtbLcp1, while lane 4
contains a negative control of material extracted from EmbCCT (21). Lipids
were analyzed by TLC using silica gel plates (5735 silica gel 60F254; Merck) and
developed in CHCl3-CH3OH-NH4OH-H2O (65:25:0.5:3.6, vol/vol/vol/vol),
and plates were sprayed with 5% ethanolic molybdophosphoric acid and
charred to visualize the lipids. (B) ES-MS analysis of decaprenyl-1-
monophosphate standard (TLC, lane 1). (C) ES-MS analysis of undecaprenyl-
1-monophosphate standard (TLC, lane 2). (D) ES-MS organic extracted ma-
terial from MtbLcp1 (TLC, lane 3).
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nally, the assay mixture was initiated by addition of highly purified
recombinant MtbLcp1. The analytical strategy for the products
formed from this assay is illustrated as a flow chart in Fig. S4 in the
supplemental material. Analysis of the fraction containing the
CHCl3-CH3OH organic extraction by TLC reveals three major
bands migrating toward the bottom of the TLC plate (Fig. 5A, lane
2). These bands correspond to 14C-labeled decaprenyl-P-P-
GlcNAc-Rha-[14C]Galf (GL-3) and decaprenyl-P-P-GlcNAc-
Rha-[14C]Galf2 (GL-4), with decaprenyl-P-P-GlcNAc-Rha-
[14C]galactan remaining at the origin of the TLC plate (12, 28).
Interestingly, the intensity of each of these bands diminished in a
titration-dependent response as the amount of MtbLcp1 increased
in the assay mix (Fig. 5A, lanes 3 and 4), which was also quantified
by densitometric analysis. When we repeated the assay at the high-
est MtbLcp1 concentration in the absence of purified PG (PPG), we
observed a product profile on the TLC with band intensities al-
most identical to that of the control reaction (Fig. 5A, lane 5).
These data clearly demonstrate that upon addition of MtbLcp1 to
the assay mixture, the relative amount of [14C]Galf-labeled mate-
rial is reduced in the extracted organic fraction. We continued our
analysis of the assay products by turning our attention to the in-
soluble fraction that contains PG and PG-linked [14C]Galf-labeled
material. Complete acid hydrolysis for the purpose of [14C]sugar
identification was conducted on the insoluble material (fraction 2
[see Fig. S4 in the supplemental material]) that contains nascent
PG with newly synthesized AG material. Hydrolysates were then
reduced and per-O-acetylated before analysis via silica TLC. Anal-
ysis of per-O-acetylated alditol acetates from this insoluble frac-
tion revealed a major band that migrated to the position of per-
O-acetylated galactitol (Fig. 5B, lane 2). Other bands that
correspond to per-O-acetylated glucitol and per-O-acetylated
N-acetyl glucitol were also identified (Fig. 5B, lane 2). However,
we observed no statistically significant variation in the intensity of
these bands across all samples and repeats and attribute this phe-
nomenon to metabolism of UDP-[14C]Gal into other sugars un-
der these reaction conditions (Fig. 5B, lane 2), and this phenom-
enon has also been previously reported (12). Overall, this
background activity [14C]Gal incorporation can be attributed to
endogenous MsLcp1 present in the M. smegmatis membrane prep-
aration used in the assay mixture (Fig. 5B, lane 2). Due to the
essentiality of Mslcp1, we were unable to culture M. smegmatis
depleted of MsLcp1 in order to derive membranes free from
MsLcp1 activity. Therefore, we adopted a strategy whereby we as-
sayed for Lcp1 ligase activity over and above endogenous back-
ground activity (Fig. 5B, lane 2). The addition of recombinant
MtbLcp1 to reaction mixtures resulted in a concomitant increase in
band density that corresponds to per-O-acetylated galactitol
(Fig. 5B, lanes 3 and 4), which is also quantified by densitometric
analysis. However, in control reaction mixtures where PPG is re-
moved from the assay mixture, we observed no significant incor-
poration of [14C]Galf-labeled material, as manifested by the
disappearance of a band corresponding to per-O-acetylated galac-
titol (Fig. 5B, lane 5). Taken together, these data clearly demon-
strate two major findings. First, we are able to directly monitor the
ligation of [14C]Galf cell wall material to PG. Second, recombinant
MtbLcp1 is capable of using decaprenyl-P-P-[14C]Galfn as a sub-
strate for subsequent attachment to PG.
DISCUSSION
After conducting a bioinformatics analysis of organisms belong-
ing to the Actinomycetales, we identified MtbLcp1 (Rv3267) as the
primary putative LCP homolog in M. tuberculosis, sharing 20%
identity with Cps2A from S. pneumoniae (see Fig. S1 in the sup-
plemental material). Since lcp1 is positioned immediately up-
stream of two genes involved in linker unit biosynthesis, in the
form of wbbL1 and rmlD (Fig. 1A), we decided to investigate the
M. smegmatis lcp1 ortholog (MSMEG_1824) as a model system to
study the molecular genetics of this gene in order to assess its
essentiality and to confirm its role as a primary LCP protein in-
volved in mycobacterial cell wall assembly.
Mycobacterial AG is a highly branched heteropolysaccharide
that serves to attach PG to the outer “mycomembrane,” and the
biosynthesis of this essential cell wall component has been exten-
sively studied (reviewed in reference 9). Since we have previously
used M. smegmatis to successfully study the molecular genetics of
mycobacterial cell wall biosynthesis (22, 24), we attempted to gen-
erate a clean deletion of Mslcp1 from M. smegmatis. However, due
to the essential nature of Mslcp1 in attaching AG to PG in the cell
envelope, we anticipated that a direct deletion of Mslcp1 would
result in a nonviable, lethal strain, and our hypothesis was justified
by our inability to generate a null mutant. The essentiality of
Mslcp1 was confirmed when we performed a CESTET essentiality
experiment (Fig. 3) (22). Generating null mutants of genes in
mycobacteria that are involved in essential aspects of cell envelope
biosynthesis is technically challenging and can be attributed to
corresponding defects in the cell wall that produce nonviable phe-
FIG 3 Essentiality of Mslcp1 inM. smegmatismc21551. (A) Growth and colony morphology ofM. smegmatis andMslcp1 conditional mutant on tryptic soy agar
with the inducer acetamide. WT, wild type. (B) CFU counts ofM. smegmatisMslcp1 conditional mutant cultured in tryptic soy broth in the presence and absence
of the inducer acetamide (data plotted represent the mean standard deviation from three independent biological replicate experiments).
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FIG 4 Binding of linker unit analogues to MtbLcp1. (A) Chemical structure of the mycobacterial linker unit and novel chemical scaffolds used as ligands to probe
the interaction of the linker unit with MtbLcp1. (B) Saturation binding experiments using intrinsic tryptophan fluorescence of MtbLcp1 to study binding of ligands
1 to 4. Data plotted represent the mean standard deviation from three independent biological replicate experiments.
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notypes. The M. smegmatis aftC mutant represents a strain of
mycobacteria for which we have succeeded in generating a signif-
icant cell wall defect via genetic manipulation (24). Due to the
complete loss of (1¡3)-arabinosyltransferase activity, the M.
smegmatis aftC mutant produces a significantly altered AG but,
crucially, still connects PG to the outer (albeit reduced) mycolate
layer (24). Unsuccessful attempts by our laboratory to generate a
direct knockout (KO) of any other gene(s) involved in cell wall
biosynthesis upstream of this event are due to the formation of
nonviable mutants which are completely unculturable. Given the
essential nature of the mycobacterial cell wall toward cell viability,
the generation of conditional mutants followed by phenotypic
characterization via the CESTET procedure is an extremely useful
tool to confirm gene essentiality. Furthermore, M. smegmatis en-
codes three additional Lcp orthologs in the forms of the products
of MSMEG_0107, MSMEG_6421, and MSMEG_5775, none of
which can complement the function of MSMEG_1824 KO. In
M. tuberculosis, two additional Lcp orthologs are encoded by
Rv3484 and Rv0822c. In this regard, the function of these remain-
ing lcp genes requires further investigation.
The presence of a hydrophobic channel within the MtbLcp1
homology model is consistent with similar cavities found within
LCP proteins fromB. subtilis and S. pneumoniae (13, 15) (Fig. 1C).
Indeed, biochemical analysis of recombinant MtbLcp1 clearly
demonstrates that decaprenyl-1-monophosphate copurifies and
is likely to be bound within the hydrophobic cavity of the protein
(Fig. 2). In order to investigate the biochemical function of Mt-
bLcp1, we chemically synthesized a panel of four ligands that rep-
resent chemical structures found within the mycobacterial AG
proximal to the linker unit and used intrinsic ITF to study the
ligand binding properties of these ligands against MtbLcp1. We
observed a ligand binding relationship that reached saturation
with a defined Bmax for each of the compounds 1 to 3, all of which
display a binding affinity in the low-micromolar range. Com-
pound 1 was synthesized to mimic the L-Rha-(1¡3)-D-GlcNAc
disaccharide moiety of the linker unit, and we recorded a KD of
58.71 M. However, our binding data clearly demonstrate that
the ligand with highest affinity for MtbLcp1 is the tetrasaccharide
Galf2-Rha-GlcNAc-O-C8 (compound 2) with a KD of 5.13 M.
Interestingly, extension of this molecule with an additional Galf
FIG 5 AG-PG ligase activity of MtbLcp1 using a radiolabeled cell-free functional assay. (A) Organic solvent-extracted fractions from 14C-labeled assay mixtures
were analyzed by TLC and developed in CHCl3-CH2OH-H2O-NH4OH (65:25:3.6:0.5, vol/vol/vol/vol) on aluminum-backed silica gel plates (5735 silica gel
60F254; Merck), and products were visualized by autoradiography, exposing the TLCs to X-ray film (Kodak X-Omat). TLC is representative of three independent
biological replicate experiments, and corresponding densitometric data plotted represent the mean standard deviation for each band. Associated P values are
as follows: *, P  0.05; **, P  0.01; ***, P  0.001. (B) Insoluble material from fraction 2 of the assay mixtures was hydrolyzed in 2 M TFA, reduced, and
per-O-acetylated. The resulting 14C-labeled per-O-acetylated alditol acetate derivatives were analyzed by TLC using ethyl acetate-hexane (4:6, vol/vol) on
aluminum-backed silica gel plates (5735 silica gel 60F254; Merck), and products were visualized by autoradiography, exposing the TLCs to X-ray film (Kodak
X-Omat), and compared to known alditol-acetate standards of D-galactose (Gal), D-glucose (Glc), and D-N-acetylglucosamine (GlcNAc). TLC is representative
of three independent biological replicate experiments, and corresponding densitometric data plotted represent the mean standard deviation for each band.
Associated P values are as follows: *, P 0.05; **, P 0.01; ***, P 0.001.
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residue (compound 3) caused a subtle 4-fold decrease in binding
affinity (Fig. 4B). For technical reasons, we were unable to synthe-
size Galf-Rha-GlcNAc-O-C8 and therefore were unable to study
the binding of a ligand that represents the linker unit with only a
single Galf extension. In a control experiment, we investigated the
ligand binding properties of Galf-(1¡4)-L-Rhap (compound 4)
toward MtbLcp1. This compound displayed no recordable affinity
toward the protein (over changes in background fluorescence),
which suggests that the presence of D-GlcNAc in the linker unit is
vital for biophysical association between protein and ligand. How-
ever, since MtbLcp1 is able to bind both the linker unit (compound
1) and the linker unit with 2 to 3 Galf residues (compounds 2 and
3, respectively), our data suggest that MtbLcp1 might catalyze the
phosphotransfer and ligation of AG to PG upon encountering a
true physiological substrate that contains a decaprenyl-
pyrophosphate-linker unit with at least one (if not two) Galf res-
idue at the nonreducing end of the glycan chain (Fig. 6).
We extended our investigation toward the development of a
cell-free functional assay to measure the ligation of AG to PG in
the presence of MtbLcp1. Chemical analysis of a reaction mixture
that contained 14C-radiolabeled AG supplemented with nascent
PG clearly shows that MtbLcp1 is capable of ligating both macro-
molecules in a titratably dependent manner (Fig. 5). However,
because this assay requires the use of mycobacterial membranes
that contain endogenous AG-PG ligase activity, an alternative ex-
planation is that recombinant MtbLcp1 could indirectly activate
this residual membrane activity. It has been previously reported
that ligation of AG to PG in mycobacteria requires concomitant
synthesis of both cell wall polymers (10, 12); however, until now,
the enzyme responsible for this activity has not been reported.
This study now provides compelling genetic and biochemical ev-
idence that MtbLcp1 is indeed the enzyme that reconciles two ma-
jor mycobacterial cell wall biosynthetic pathways by forming a
covalent phosphodiester between PG and AG (Fig. 6). The discov-
ery of MtbLcp1 sheds new light on a key reaction involved during
late-stage cell wall assembly which is likely to be critical for all
members of the Actinomycetales harboring AG attached to PG via
a phosphodiester linker unit.
In S. aureus, the first two genes of the WTA pathway (tagO and
tagA) are nonessential and can be deleted without retarding
growth of both mutant strains (33, 34). However, deletion of any
of the subsequent WTA-synthesizing enzymes (TagBDFGH or
TarIJL) produces a lethal phenotype, unless each corresponding
mutant also contains an inactivation in tagO or tagA (34). A pro-
posed hypothesis to explain this synthetic viable phenotype relates
to the limited availability of the bactoprenol lipid carrier in the
cytoplasmic membrane, which is required for not only WTA bio-
synthesis but also lipid II biosynthesis, which ultimately leads to
FIG 6 Schematic diagram of the latter stages of mycobacterial cell wall biosynthesis. (1) Translocation of galactan polymer across plasma membrane. Lcp1 then
recognizes and binds the linker unit (i.e., represented by compounds 2 and 3). (2) Phosphotransferase activity links AG to the 6=-OH of muramyl residues,
releasing decaprenyl-1-monophosphate for recycling. (3) Newly bound AG is released by Lcp1 to go on to form mature mAGP. Additional synthesis of new PG,
requiring AG addition by Lcp1, takes place simultaneously.
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PG assembly (34). Furthermore, similar effects have been demon-
strated in S. aureus by chemical means, whereby targocil, an in-
hibitor of late-stage WTA biosynthesis, causes an accumulation of
undecaprenyl-linked intermediates, thus preventing recycling of
the undecaprenyl-phosphate lipid carrier, causing synthetic le-
thality (35). This phenomenon most likely reflects the phenotypic
consequence of an Mslcp1 deletion in M. smegmatis. Upon acet-
amide withdrawal from growing cultures ofM. smegmatisMslcp1
pMV306-ACET-Mslcp1, expression of Mslcp1 diminishes, which
will likely result in two major effects: (i) loss of AG-PG ligase
activity and (ii) a concomitant increase in the decaprenyl-
pyrophosphoryl-linked galactan intermediate(s). While the former
effect induces a devastating cell wall lesion, the latter effect will cause
a dramatic reduction in available decaprenyl monophosphate that
is also required for PG biosynthesis, via loss of lipid II. Further-
more, Actinomycetales such as M. tuberculosis and C. glutamicum
also use decaprenyl phosphate in the production of decaprenyl-
phosphoarabinose (DPA) and decaprenyl-phosphomannose
(DPM), which is directed toward the formation of D-arabinan and
lipomannan (which is the precursor to lipoarabinomannan
[LAM]), respectively (36, 37). Benzothiazinones (BTZs) are a class
of compounds that are particularly potent inhibitors of mycobac-
terial growth. BTZs target DprE1, which is an oxidoreductase in-
volved in the epimerization of decaprenyl-phosphoribose (DPR) to
decaprenyl-phosphoarabinose (DPA), thus arresting D-arabinan
biosynthesis (38, 39). However, it has recently been shown that BTZ’s
potent mode of action is attributed to the blocking of decaprenyl
monophosphate recycling, a process which is required to allow cell
wall biosynthesis to function properly (40). In this regard, Lcp1 is a
potential drug target, since its inhibition will affect late-stage cell wall
maturation and reduce the availability of decaprenyl monophos-
phate, leading to synthetic lethality.
MATERIALS AND METHODS
Homology modeling and sequence alignment. The amino acid sequence
of M. tuberculosis Rv3267 (MtbLcp1, Swiss-Prot ID P96872_MYCTU) was
submitted for three-dimensional (3D) structure prediction using the
I-TASSER server (19, 20), and the conformation of the secondary struc-
tural features for the resultant MtbLcp1 model was predicted using pdb-
sum (41). The homology model of MtbLcp1 was analyzed in comparison to
the Cps2A structures from S. pneumoniae (PDB ID 2XXP) (13).
Chemicals, reagents, and enzymes. All chemicals and solvents were
from Sigma-Aldrich (Dorset, United Kingdom), Bio-Rad (CA, USA), and
Fisher Chemicals (United Kingdom) unless otherwise stated and were of
analytical grade or equivalent. Plasmids were propagated during cloning
in Escherichia coli Top10 cells (Invitrogen). All restriction enzymes and
Phusion DNA polymerase enzyme were sourced from New England Bio-
labs. The Bioline quick ligation kit was used to perform ligation reactions.
Oligonucleotides were from MWG Biotech Ltd., and PCR fragments were
purified using the QIAquick gel extraction kit (Qiagen). Plasmid DNA
was purified using the QIAprep purification kit (Qiagen). The prepara-
tion of oligosaccharides 1 to 3 using methods previously reported (42) is
described in Text S1 in the supplemental material. Disaccharide 4 was
prepared previously (43).
Bacterial strains and growth conditions. E. coliTop10 cells were rou-
tinely grown in Luria-Bertani broth or Luria-Bertani agar (LB; Difco) at
37°C.E. coliBL21(DE3) cells were grown in Terrific Broth (Difco) at 37°C.
M. smegmatis mc2155 was grown in tryptic soy broth (TSB; Difco) con-
taining Tween 80 supplemented with the appropriate antibiotic(s)
(25 g/ml kanamycin [Kan] and/or 100 g/ml hygromycin).
Construction of recombinant plasmids. For generation of the Mt-
bLcp1 expression vector, a 1,389-bp region of Rv3267 was cloned from
M. tuberculosis H37Rv genomic DNA using the following primer pairs
(restriction sites underlined): Rv3267FW (5=-GATCGATCCATATGCG
GTCGTTCGAAGACGGCATCTTCCAC-3=) and Rv3267DN (5=-GATC
GATCAAGCTTTCAGTTGATGCACTCCGGCGCGTCGGAG-3=). The
PCR product was ligated into pET28b vector and cut with NdeI and Hin-
dIII, yielding pET28b-Mtblcp1. The plasmid was subsequently sequenced
to check for construct integrity (Eurofins MWG).
For generating an integrative vector containing MSMEG1824, the
open reading frame (ORF) was amplified from M. smegmatis mc2155
genomic DNA using the primers MS1824FW (5=-GATCGATCGATATC
TTGATCAGGTCCATTGCTGTGGCCGCA-3=) and MS1824DN (5=-GA
TCGATCAAGCTTTCAGTTCACGCACTGCGGGTCGTTGGC-3=).
The DNA amplicon was digested with HindIII and EcoRV and subse-
quently cloned into pMV306 together with the Pacetamidase promoter re-
gion from pSD26 as described previously (22), thus yielding pMV306-
ACET-MSMEG1824 (pMV306-ACET-Mslcp1). The plasmid was
subsequently sequenced to check for construct integrity (Eurofins
MWG).
For generation of the Mslcp1 phasmid, approximately 1-kb se-
quences of the upstream and downstream regions of MSMEG1824 were
PCR amplified fromM. smegmatismc2155 genomic DNA with the primer
pairs MS1824LL (5=-TTTTTTTTCCATAAATTGGCGACCACCAGGGG
GCGGGCATCGTCCA-3=) and MS1824LR (5=-TTTTTTTTCCATTTCT
TGGACCGGGGCAGGCGGCATGGTCGGGCGC-3=) and MS1824RL
(5=-TTTTTTTTCCATAGATTGGACGACGCCACCGGTGAACGCATC
GAGC-3=) and MS1824RR (5=-TTTTTTTTCCATCTTTTGGGCCGACG
ACAGGCTGCTCGACGACTAC-3=), respectively (all primers had
Van91I recognition sites incorporated at the 5= end). The PCR fragments
were digested with Van91I and directly cloned into Van91I-digested
p0004S (gift from T. Hsu and W. R. Jacobs, Jr., Albert Einstein College of
Medicine, NY). Recombinant plasmids obtained after transformingE. coli
Top10 cells were digested with Van91I for confirmation and sequenced.
One plasmid, pMSMEG1824, was linearized by PacI digestion and pack-
aged into the temperature-sensitive mycobacteriophage phAE159, as pre-
viously described (44), to yield phasmid DNA of the knockout phage
phMSMEG1824 (phMslcp1).
Generation of the Mslcp1 conditional mutant. The M. smegmatis
Mslcp1 conditional mutant was generated using the CESTET procedure
(22). Briefly, a merodiploid strain was first generated by introducing
pMV306-ACET-Mslcp1 by electroporation into M. smegmatis mc2155
(22). The merodiploid strain M. smegmatis mc2155::pMV306-ACET-
Mslcp1 was then subjected to specialized transduction as previously
described (22) using a temperature-sensitive, recombinant phage,
phMslcp1, designed to replace MSMEG1824 with a hygromycin resis-
tance marker. Transductants were selected at the nonpermissive temper-
ature of 37°C on selective plates containing 25 g/ml kanamycin,
100 g/ml hygromycin B, and 0.2% (wt/vol) acetamide. Allelic exchange
in hygromycin-resistant transductants was confirmed by PCR and South-
ern blotting.
Conditional depletion of the Mslcp1 conditional mutant. The
Mslcp1 conditional mutant was grown in tryptic soy broth (TSB; Difco)
containing 0.05% Tween 80, 25 g/ml kanamycin, 100 g/ml hygromy-
cin B, and 0.2% (wt/vol) acetamide and subsequently passaged twice in
medium with and without acetamide. Ten-milliliter cultures were allowed
to grow for a further 56 h at 37°C with shaking. Ten-microliter samples
were taken at 8-h intervals and plated on TBS agar plates supplemented
with 25 g/ml kanamycin and 100 g/ml hygromycin B with or without
0.2% (wt/vol) acetamide to measure CFU.
Expression and purification of MtbLcp1. The plasmid pET28b-
Mtblcp1 was transformed into E. coli BL21(DE3) cells, spread onto LB agar
plates containing 50 mg/ml Kan, and incubated at 37°C for 18 h. Single
colonies were selected to inoculate 5 ml LB broth containing 50 g/ml
Kan and were incubated at 37°C overnight. The overnight cultures were
then used to inoculate 1 liter Terrific Broth containing 50 mg/ml Kan,
which was incubated (37°C, 180 rpm) until an optical density at 600 nm
Lcp1 Ligates AG to PG in M. tuberculosis
















(OD600) of 0.5 was reached. Protein production was then induced by the
addition of 1 mM IPTG (isopropyl--D-thiogalactopyranoside; 12 h at
16°C). Cells were harvested via centrifugation at 6,000  g for 15 min
(4°C). Supernatant was discarded, and cells were washed in 30 ml
phosphate-buffered saline (PBS). Pellets were stored at20°C until fur-
ther use. A pellet was defrosted and then resuspended in 30 ml lysis buffer
(50 mM KH2PO4 [pH 7.9], 300 mM NaCl, 20 mM imidazole), including
a proteinase inhibitor tablet (Roche). The mixture was subsequently son-
icated using a Soniprep 150 ultrasonic disintegrator (MSE) (30 s on, 30 s
off, 10 cycles). The solution was then centrifuged at 27,000 g for 40 min
(4°C), and the supernatant was retained (clarified lysate). Protein was
loaded onto a HisTrap 5-ml chelating HP column (GE Healthcare),
charged with 0.1 M NiCl2, equilibrated in lysis buffer, and eluted via a
stepwise 50 to 500 mM imidazole concentration gradient (in lysis buffer).
Fractions were analyzed by 12% SDS-PAGE to check for purity, and those
fractions containing purified protein were dialyzed into dialysis buffer
(25 mM Tris-HCl [pH 7.9], 10 mM NaCl, and 10% glycerol). Protein
concentration was measured using a Bradford assay.
Extraction of decaprenyl-1-monophosphate from MtbLcp1. Two
milliliters of recombinant MtbLcp1 (2 mg/ml dissolved in dialysis buffer)
was combined with 2 ml CHCl3 and 1 ml of CH3OH and heated at 60°C
for 2 h with agitation. After centrifugation at 5,000  g for 10 min, the
lower organic fraction was recovered and dried under nitrogen. The re-
sulting extract was resuspended in CHCl3-CH3OH (100 l, 2:1, vol/vol)
and analyzed by electrospray mass spectrometry (ES-MS) in the negative
mode on a Micromass LCT mass spectrometer. An identical extraction
was also carried out on 2 mg/ml of EmbCCT (21), which was used as a
negative control.
Ligand binding experiments. Intrinsic tryptophan fluorescence (ITF)
ligand binding experiments of MtbLcp1 with saccharide ligands were con-
ducted on a Hitachi F7000 fluorescence spectrophotometer with the tem-
perature thermostatically regulated to 25°C. MtbLcp1 was diluted to
0.026 M with dialysis buffer, and fluorescence spectra were measured at
an excitation wavelength of 280 nm and emission wavelength of 300 to
400 nm with an excitation and emission slit width of 5 nm using a 500-l
crystal cuvette. ITF maximum (Femissionmax) was recorded at  341 nm,
providing a basal Femission coordinate for the collection of subsequent ITF
data. Increasing concentrations of ligands representing the linker unit
(compounds 1 to 4) were added to the cuvette. The change in fluorescence
emission (Femission) was calculated by subtracting Femission (recorded
2 min after each ligand addition) from Femissionmax. Changes of back-
ground fluorescence observed upon addition of equivalent volumes of
dialysis buffer (the solvent in which compounds 1 to 4 were dissolved)
were subtracted from the overall change in fluorescence, and the data were
then plotted against ligand concentration, [L] (3 independent biological
experiments). A plot ofFemission at  341 nm versus [L] was fitted to a
one-site specific binding equation using GraphPad Prism 5 software:
Femission Fmax [L]/(KD [L]).
Preparation of nascent mycobacterial peptidoglycan. One liter of
M. smegmatis mc2155 was cultured in TSB as described above and har-
vested by centrifugation. Pelleted M. smegmatis cells were resuspended in
H2O before addition of CHCl3-CH3OH (1:1, vol/vol) to create CHCl3-
CH3OH-H2O (10:10:3, vol/vol/vol) single phase. The suspension was
centrifuged at 3,300  g for 15 min, the resulting supernatant was dis-
carded, and the pellet was resuspended in 30 to 40 ml H2O. The cell
suspension was sonicated (60 s on, 90 s off, 15 cycles) before addition of
1% (vol/vol) Triton X-100. The cell suspension was incubated at room
temperature for 16 h and then centrifuged at 3,300  g for 15 min. The
crude insoluble material from the above extraction was extracted three
times with 2% SDS in PBS at 95°C for 1 h; washed with water, 80%
(vol/vol) acetone in water, and acetone; and finally lyophilized to yield a
highly purified cell wall mAGP preparation (45). Mycolic acids were re-
moved from mAGP by treatment with 0.5% (wt/vol) KOH in methanol at
37°C for 4 days. The treated mAGP was collected by centrifugation at
27,000  g for 20 min and then washed repeatedly with methanol and
recentrifuged at 27,000  g, and the pellet was recovered. The mycolic
acids were then extracted from the treated mAGP using diethyl ether and
recentrifuged at 27,000 g, and the pellet (AGP) and soluble mycolic acid
methyl esters were recovered in the diethyl ether supernatant. The extrac-
tion process using diethyl ether was repeated three times. The AGP com-
plex was hydrolyzed with 0.2 M H2SO4 at 85°C for 30 min and neutralized
with BaCO3 (32). The supernatant (which contained solubilized arabi-
nogalactan [AG]) was removed via centrifugation at 27,000  g for
30 min. The residual pellet (containing the highly purified peptidoglycan
[PPG] fraction) was finally extensively washed with water, freeze-dried,
and stored at20°C.
Functional biochemical assay for MtbLcp1. Membranes (containing
membrane-bound enzymes involved in lipid-linked cell wall biosynthetic
processes) and P60 (a Percoll-derived cell-free fraction rich in carbohy-
drate and enzymes associated with cell wall processes as described in ref-
erence 46) fractions from M. smegmatis were prepared as described pre-
viously (24, 26, 46) and resuspended in buffer A (50 mM
morpholinepropanesulfonic acid [MOPS; pH 7.9] containing 5 mM
-mercaptoethanol and 10 mM MgCl2) to a final concentration of
15 mg/ml and 10 mg/ml for membrane and P60 fractions, respectively.
The basic assay mix consisted of buffer A, 0.5 mg membranes (33 l),
0.5 mg of P60 (50 l), 0.2 mM ATP, 0.2 mM NADH, 0.1 Ci of UDP-D-
[U-14C]galactose (specific activity, 300 mCi/mmol; ARC Radiochemi-
cals), and 1 mg PPG; the reaction was initiated with the addition of
0.1 mg/ml MtbLcp1 (final volume of 200l); and the reaction mixture was
incubated for 17 h at 37°C. Reactions were quenched by the addition of
1,333l of CHCl3-CH3OH (1:1, vol/vol). After mixing and centrifugation
at 27,000 g for 15 min at 4°C, the supernatant was removed and dried
under nitrogen and the pellet was retained for further processing. The
dried supernatant was resuspended into 2 ml of CHCl3-H2O (1:1, vol/
vol), and the lower organic phase (fraction 1) was removed and dried
under nitrogen. Material in fraction 1 was subjected to TLC using CHCl3-
CH2OH-H2O-NH4OH (65:25:3.6:0.5, vol/vol/vol/vol) on aluminum-
backed silica gel plates (5735 silica gel 60F254; Merck), and products were
visualized by autoradiography, exposing the TLCs to X-ray film (Kodak
X-Omat). The pellet from the previous step was resuspended into 1 ml
H2O-C2H5OH-(C2H5)2-pyridine-NH4OH (15:15:5:1:0.017, vol/vol/
vol/vol/vol) and left at room temperature to be extracted for 2 h.
Samples were again centrifuged at 27,000  g for 15 min, and super-
natant was discarded. The remaining pellet (fraction 2) was resus-
pended in 200 l H2O. All fractions were quantified by liquid scintil-
lation counting using 10% of the labeled material and 5 ml of
EcoScintA (National Diagnostics, Atlanta, GA).
Material in fraction 2 was hydrolyzed in 2 M trifluoroacetic acid (TFA)
and reduced with NaBH4, and the resultant alditols were per-O-acetylated
as described previously (47). The resulting 14C-labeled per-O-acetylated
alditol acetate derivatives were analyzed by TLC using ethyl acetate-
hexane (4:6, vol/vol) on aluminum-backed silica gel plates (5735 silica gel
60F254; Merck), and products were visualized by autoradiography, ex-
posing the TLCs to X-ray film (Kodak X-Omat) and comparing them to
known standards. All experiments were performed in triplicate as biolog-
ical replicates.
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